Peltz S W, Katzenellenbogen B S, Kneifel M A, Mangel W F
Endocrinology. 1983 Mar;112(3):890-7. doi: 10.1210/endo-112-3-890.
We have characterized the molecular properties of the plasminogen activators in different cell types comprising the immature and the estrogen-stimulated rat uterus and in rat uterine luminal fluid. There were two plasminogen activators in the immature (day 20) rat uterus with apparent molecular weights, determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, of 70,000 and 46,000. Both plasminogen activators were present in epithelial and in stromal plus myometrial cell fractions of the immature uterus, and after stimulation by 17 beta-estradiol, no new plasminogen activators were detected in either cell fraction. The Michaelis constants (Km) for the activation of dog plasminogen by extracts from epithelial cells and from stromal plus myometrial cells obtained from either immature or 17 beta-estradiol-stimulated uteri were similar (approximately 11 microM). The maximal velocity (Vmax), normalized to protein concentration, increased 2.5-fold in the stromal plus myometrial cell fraction and 6.5-fold in the epithelial cell fraction, upon hormone stimulation (2 micrograms 17 beta-estradiol/day X rat for 3 days). The greatest concentration of plasminogen activator activity was found in the luminal fluid from estrogen-stimulated uteri, where the Vmax per mg protein was more than 10-fold greater than that in the cell fractions from estrogen-stimulated uteri. The plasminogen activator activity of luminal fluid was inhibited by diisopropyl fluorophosphate and rho-nitrophenyl rho-guanidinobenzoate, was not inhibited by human alpha-1-proteinase inhibitor and human antithrombin III, and was inhibited by high, but not low, concentrations of soybean trypsin inhibitor and bovine pancreatic trypsin inhibitor. These studies indicate that the plasminogen activators in different cell types comprising the uterus are similar and show that the estrogen enhancement of uterine plasminogen activator activity is the result of an increase in Vmax. The presence, upon hormone stimulation, of an apparent concentration gradient of increasing plasminogen activator activity through the uterus from myometrium to epithelium to luminal fluid may be a reflection of the dynamic role of this protease in the physiology of the uterus.
我们已经对不同细胞类型中的纤溶酶原激活剂的分子特性进行了表征,这些细胞类型包括未成熟的和雌激素刺激后的大鼠子宫以及大鼠子宫腔液。在未成熟(第20天)大鼠子宫中有两种纤溶酶原激活剂,通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳测定,其表观分子量分别为70,000和46,000。这两种纤溶酶原激活剂都存在于未成熟子宫的上皮细胞以及基质加肌层细胞组分中,并且在受到17β-雌二醇刺激后,在任何一种细胞组分中均未检测到新的纤溶酶原激活剂。从未成熟或17β-雌二醇刺激的子宫中获得的上皮细胞以及基质加肌层细胞提取物激活犬纤溶酶原的米氏常数(Km)相似(约11μM)。在激素刺激(2μg 17β-雌二醇/天×大鼠,持续3天)后,以蛋白质浓度标准化的最大反应速度(Vmax)在基质加肌层细胞组分中增加了2.5倍,在上皮细胞组分中增加了6.5倍。在雌激素刺激的子宫的腔液中发现了最高浓度的纤溶酶原激活剂活性,其中每毫克蛋白质的Vmax比雌激素刺激的子宫的细胞组分中的Vmax大10倍以上。腔液中的纤溶酶原激活剂活性受到二异丙基氟磷酸酯和对硝基苯基对胍基苯甲酸酯的抑制,不受人α1-蛋白酶抑制剂和人抗凝血酶III的抑制,并且受到高浓度但非低浓度的大豆胰蛋白酶抑制剂和牛胰蛋白酶抑制剂的抑制。这些研究表明,构成子宫的不同细胞类型中的纤溶酶原激活剂相似,并表明子宫纤溶酶原激活剂活性的雌激素增强是Vmax增加的结果。在激素刺激后,从子宫肌层到上皮再到腔液存在纤溶酶原激活剂活性逐渐增加的明显浓度梯度,这可能反映了这种蛋白酶在子宫生理学中的动态作用。